SCHEMBL29587170

SCHEMBL29587170

CC(C)C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CO)C(N)=O

nearest known ligand 0.67

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
KISS1R Q969F8 14/20 0.67
IL1RN P18510 2/20 0.64
ERAP2 Q6P179 2/20 0.64
ERAP1 Q9NZ08 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29586130 0.93 ERAP2 (0.68) KISS1RIL1RNERAP2ERAP1
SCHEMBL31452846 0.92 ERAP2 (0.70) KISS1RIL1RNERAP2ERAP1
SCHEMBL31430944 0.90 ERAP2 (0.69) IL1RNERAP2ERAP1
SCHEMBL30949446 0.89 KISS1R (0.63) KISS1RIL1RNERAP2ERAP1
SCHEMBL29738146 0.88 KISS1R (0.75) KISS1R
SCHEMBL15929992 0.88 KISS1R (0.65) KISS1R
SCHEMBL30845356 0.88 KISS1R (0.69) KISS1R
SCHEMBL11649947 0.88 IL1RN (0.73) KISS1RIL1RNERAP2ERAP1
SCHEMBL30845371 0.87 KISS1R (0.71) KISS1R
SCHEMBL23314250 0.87 KISS1R (0.68) KISS1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240009331-A1 UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR TARGETED RADIOLABELED PEPTIDE CONJUGATES CURASIGHT A/S (DK) 2024-01-11 US claimed
EP-4255506-A1 UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR TARGETED RADIOLABELED PEPTIDE CONJUGATES Curasight A/S (DK) 2023-10-11 EP claimed
US-20230022032-A1 uPAR-TARGETED PHOTOTHERMAL OPTICAL PROBES FOR PHOTOTHERMAL THERAPY RIGSHOSPITALET (DK) 2023-01-26 US claimed
US-20220401585-A1 A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE RIGSHOSPITALET (DK) 2022-12-22 US claimed
EP-4081256-A1 UPAR-TARGETED PHOTOTHERMAL OPTICAL PROBES FOR PHOTOTHERMAL THERAPY Rigshospitalet (DK) 2022-11-02 EP claimed
WO-2022117454-A1 UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR TARGETED RADIOLABELED PEPTIDE CONJUGATES RIGSHOSPITALET (DK) 2022-06-09 WO claimed
CN-114555623-A Urokinase plasminogen activator receptor targeting peptides 丹麦国家医院 2022-05-27 CN claimed
EP-3999094-A1 A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE Rigshospitalet (DK) 2022-05-25 EP claimed
EP-3999123-A1 A RECEPTOR-TARGETING CONJUGATE WITH AN EFFECTIVE PHARMACOKINETIC PROFILE Fluoguide A/S (DK) 2022-05-25 EP claimed
US-20260077066-A1 RECEPTOR-TARGETING CONJUGATE WITH AN EFFECTIVE PHARMACOKINETIC PROFILE FLUOGUIDE AS 2026-03-19 US disclosed
CN-114555623-B Urokinase plasminogen activator receptor targeting peptides 丹麦国家医院 2024-10-25 CN disclosed
US-20240009331-A1 UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR TARGETED RADIOLABELED PEPTIDE CONJUGATES CURASIGHT A/S (DK) 2024-01-11 US disclosed
EP-4255506-A1 UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR TARGETED RADIOLABELED PEPTIDE CONJUGATES Curasight A/S (DK) 2023-10-11 EP disclosed
US-20230022032-A1 uPAR-TARGETED PHOTOTHERMAL OPTICAL PROBES FOR PHOTOTHERMAL THERAPY RIGSHOSPITALET (DK) 2023-01-26 US disclosed
US-20220401585-A1 A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE RIGSHOSPITALET (DK) 2022-12-22 US disclosed
EP-4081256-A1 UPAR-TARGETED PHOTOTHERMAL OPTICAL PROBES FOR PHOTOTHERMAL THERAPY Rigshospitalet (DK) 2022-11-02 EP disclosed
US-20220257799-A1 A RECEPTOR-TARGETING CONJUGATE WITH AN EFFECTIVE PHARMACOKINETIC PROFILE FLUOGUIDE A/S (DK) 2022-08-18 US disclosed
WO-2022117454-A1 UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR TARGETED RADIOLABELED PEPTIDE CONJUGATES RIGSHOSPITALET (DK) 2022-06-09 WO disclosed
CN-114555623-A Urokinase plasminogen activator receptor targeting peptides 丹麦国家医院 2022-05-27 CN disclosed
EP-3999094-A1 A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE Rigshospitalet (DK) 2022-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230022032-A1 uPAR-TARGETED PHOTOTHERMAL OPTICAL PROBES FOR PHOTOTHERMAL THERAPY PLAUR, PLAU, PLG KISS1R 2103/4885IL1RN 202/4885ERAP2 169/4885
US-20220401585-A1 A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE PLAUR, PLAU, PLG KISS1R 729/4885IL1RN 179/4885ERAP2 421/4885
US-20260077066-A1 RECEPTOR-TARGETING CONJUGATE WITH AN EFFECTIVE PHARMACOKINETIC PROFILE FCGR2A, FCGR1A, FCGR3B KISS1R 310/4885IL1RN 139/4885ERAP2 1698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.